pharmaceutical daily news

Beximco Pharmaceuticals got approval from the US Food and Drug Administration (FDA), for its Nadolol tablets, a generic equivalent of Bristol-Myers Squibb’s Corgard, for hypertension and chest pain, angina pectoris. 

Apricus Biosciences will merge with Seelos Therapeutics, Inc., a privately-held biotechnology company, in an all-stock transaction, it announced on Monday, and will focus on bringing to shelves central nervous system (CNS) therapeutics.

Destiny Pharma’s first of two Phase 1 safety clinical studies of testing XF-73’s potential to cause dermal irritation, as Destiny’s lead candidate for the prevention of post-surgical staphylococcal infections, brought good news with positive results, which support the potential of XF compounds in dermal infection indications and also reinforce the target

PureTech Health’s new internal programme focused on treating central nervous system (CNS) disorders via modulation of the brain’s lymphatic system, based on the work of Jonathan Kipnis, from Centre for Brain Immunology and Glia, at the University of Virginia School of Medicine, was published in Nature.

WuXi STA Pharmaceutical’s Active Pharmaceutical Ingredient (API) production site in China, at Jinshan, Shanghai, has passed its fourth inspection from the U.S. Food and Drug Administration (USFDA). WuXi STA is the first CDMO in China that is approved to supply commercial APIs for innovative drugs by regulatory agencies in the USA,

PureTech Health’s independent affiliate, resTORbio reported positive topline results from its Phase 2b clinical study with TORC1 inhibitor, that enrolled 652 elderly patients at increased risk of death related with respiratory tract infections (RTIs).

Midatech Pharma said in its trading update it remains on track to meet market expectations for 2018, as it expects total gross product revenues of approximately £5.8 million to June 2018, a 16% increase from the £5.0 million recorded in the six months to June 2017.

AstraZeneca will sell the commercial rights to prescription medicine for the treatment of heart failure and hypertension, Atacand and Atacand Plus in Europe to Cheplapharm Arzneimittel GmbH, for $200 million on completion of the agreement, plus a time-bound payment of $10 million and sales-contingent milestones.